- The NWHN’s statement on the nomination of Dr. Stephen Hahn to FDA Commissioner
November 1, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington D.C.- Today, the Trump Administration announced the nomination of Dr. Stephen Hahn to become the next US Food and Drug Administration Commissioner. The National Women’s Health Network calls on Dr. Hahn to publicly commit ...
- The NWHN statement on the Title X Gag Rule taking effect
June 24, 2019
Last year, the Trump-Pence administration rushed through a proposed rule to gut Title X, the country’s family planning program to help low-income individuals access affordable birth control and reproductive health care.
Today, a federal appeals court overturned three lower courts and allowed the Title X gag rule to go into effect. This is a devastating ...
- The NWHN’s Statement on the FDA’s approval of Vyleesi
June 21, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: 425-749-1886
The following statement can be attributed to Cynthia A. Pearson,
Executive Director of the National Women’s Health Network.
Washington D.C. — The National Women’s Health Network (the NWHN) is disappointed in the United States Food and Drug Administration’s (FDA) decision to approve the drug bremelanotide (brand name: Vyleesi) and urges women to ...
- Women’s health groups to Congress: We need strong cosmetics standards
June 20, 2019
For Immediate Release
Contact: Evita Almassi, ealmassi@nwhn.org
Washington, D.C. – Led by the National Women’s Health Network, 42 national, state, and local organizations united by their shared interest in lifting up the voices of women sent a letter today to the House Energy and Commerce Committee applauding the committee for working on a bipartisan discussion draft to ...
- The NWHN’s statement on the results of the Evidence for Contraceptive Options and HIV trial (ECHO)
June 14, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
The National Women’s Health Network (The NWHN) is pleased that the results of the ECHO trial provide reassuring evidence that Depo Provera does NOT significantly increase the risk of HIV infection when compared to ...
- The NWHN’s statement on the FDA ordering manufacturers of surgical mesh to stop selling devices for uterine prolapse
April 16, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington, D.C. — Today, the U.S. Food and Drug Administration ordered the manufacturers of all remaining surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse (POP) to stop selling and ...
- The NWHN’s statement on the FDA ordering Sprout Pharmaceuticals to retain black box label warning women not mix Addyi and alcohol
April 12, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington D.C. — Yesterday the U.S. Food and Drug Administration ordered Sprout Pharmaceuticals to update the label of their female libido pill, flibanserin (brand name: Addyi). The label change says women should ...
- The NWHN’s statement in response to FDA approving Evenity
April 10, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington D.C.- Yesterday, the US Food and Drug Administration approved a new treatment romosozumab, brand name Evenity, from drugmakers Amgen and UCB for osteoporosis in postmenopausal women who are at high risk ...
- The NWHN advises women to be cautious about using flibanserin until new studies are fully vetted
March 26, 2019
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
WASHINGTON D.C. — Women should not use flibanserin or any drug unless they have sufficient information to weigh benefits against risks. Sprout Pharmaceuticals’ new alcohol studies should be reviewed with a healthy skepticism, until they have been vetted ...
- NWHN statement in response to the FDA’s action against Aid Access
March 12, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington D.C.- In a letter released Tuesday, the FDA warned online abortion pill provider AidAccess.org to immediately stop importing mifepristone and misoprostol, the two drugs that make up the most ...
- The NWHN’s statement on the resignation of FDA Commissioner Scott Gottlieb
March 5, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington D.C.- Today, US Food and Drug Administration Commissioner Scott Gottlieb announced his plan to leave the FDA in about a month.
Prior to his confirmation, the NWHN raised concerns about Gottlieb’s approach to women’s health, his close ties to the pharmaceutical industry, and ...
- The NWHN’s Statement on Title X Rule Release
February 22, 2019
For Immediate Release
Contact: Evita Almassi, ealmassi@nwhn.org
The following statement can be attributed to Sarah Christopherson, Policy Advocacy Director at the National Women’s Health Network
Washington, D.C. – Today, the Trump-Pence administration is once again attacking women’s reproductive health. Last year, HHS rushed through a proposed rule to gut Title X, the country’s only domestic family planning grant ...
